APA (7th ed.) Citation

Kimball, A. B., Jemec, G. B. E., Sayed, C. J., Kirby, J. S., Prens, E., Ingram, J. R., . . . Zouboulis, C. C. (2024). Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): Two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet, 403(10443), 2504. https://doi.org/10.1016/S0140-6736(24)00101-6

Chicago Style (17th ed.) Citation

Kimball, Alexa B., et al. "Efficacy and Safety of Bimekizumab in Patients with Moderate-to-severe Hidradenitis Suppurativa (BE HEARD I and BE HEARD II): Two 48-week, Randomised, Double-blind, Placebo-controlled, Multicentre Phase 3 Trials." Lancet 403, no. 10443 (2024): 2504. https://doi.org/10.1016/S0140-6736(24)00101-6.

MLA (9th ed.) Citation

Kimball, Alexa B., et al. "Efficacy and Safety of Bimekizumab in Patients with Moderate-to-severe Hidradenitis Suppurativa (BE HEARD I and BE HEARD II): Two 48-week, Randomised, Double-blind, Placebo-controlled, Multicentre Phase 3 Trials." Lancet, vol. 403, no. 10443, 2024, p. 2504, https://doi.org/10.1016/S0140-6736(24)00101-6.